Navigation Links
Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial

~ Valopicitabine achieved both primary and secondary endpoints of study; no negative drug-drug interaction was observed between valopicitabine and ribavirin ~

CAMBRIDGE, Mass., June 12, 2007 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. today announced results from a phase II study designed to evaluate triple combination therapy, consisting of valopicitabine (NM283), Idenix's lead drug candidate for the treatment of hepatitis C, pegylated interferon and ribavirin compared to pegylated interferon and ribavirin, the current standard of care, in patients infected with the genotype-1 strain of the hepatitis C virus (HCV). This study demonstrated no pharmacokinetic or pharmacodynamic drug-drug interaction between valopicitabine and ribavirin. The triple combination showed consistently higher rates of HCV PCR-negativity, defined as serum HCV RNA levels below 20 copies/mL, compared to the standard of care at every point analyzed in this study. Additionally, the tolerability of the triple combination was satisfactory, with only three discontinuations from the study.

"I am very encouraged to observe this degree of viral clearance coupled with a very low rate of discontinuations in patients treated with the triple combination of valopicitabine, pegylated-interferon and ribavirin in this study," said Dr. Fred Poordad, Chief of Hepatology and Liver Transplantation, Cedars Sinai Medical Center, and an investigator in this study. "These data represent an important achievement in the development of novel HCV combination therapy."

Study Design and Results

The three-arm, partially blinded, randomized study enrolled 117 treatment- naive, HCV genotype-1 infected patients at approximately 20 centers in the United States. Patients in arm A (n=39) received 200 mg/day of valopicitabine and pegylated interferon alpha 2a; patients in arm B (n=39) received 200 mg/day of valopicitabine, weight-based dosing o
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Idenix Reports Results from Two Phase IIb Studies of the Combination of Valopicitabine and Pegylated Interferon in Hepatitis C Genotype-1 Patients at the 42nd Annual Meeting of the European Association for the Study of the Liver
2. New Data Show Pfizers Axitinib Prolonged Overall Survival in Advanced Pancreatic Cancer When Combined with Standard of Care Chemotherapy
3. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
4. Low-Dose Steroid Combined With Lenalidomide Prolongs Survival Compared With High-Dose Steroid for Multiple Myeloma Treatment
5. RTA 402 Shown to Protect Animals Against Toxicities of Standard Cancer Treatments
6. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
7. Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care
8. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
9. Clinical Trial Results Change Standard of Care for Pancreatic Cancer Patients, Future Therapies Discussed
10. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
11. Phase 2 Clinical Results of Ganite Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO
Post Your Comments:
(Date:6/2/2015)...  ErgoNurse, the leader in bedside safety management solutions, and ... the United States , have formalized a partnership ... skilled nursing markets. ... Thousands of healthcare professionals in ... of the ErgoNurse products to stop unnecessarily utilizing their backs ...
(Date:6/2/2015)... announced today they are expanding their reach nationally by providing customers with on-site 17025 accredited pipette calibrations. ... ... ... ... Photo - http://photos.prnewswire.com/prnh/20150601/219758 ...
(Date:6/2/2015)... Today AmerisourceBergen, a global healthcare solutions leader, ... Olive Branch, MS ; ... . The facilities will operate within AmerisourceBergen,s existing ... increase supply chain efficiency and enhance patient care. ... ongoing investments, more than $1 billion over the last ...
Breaking Medicine Technology:ErgoNurse and Briggs Healthcare Positioned to Completely Eliminate the Unnecessary Cost of Healthcare-Related Back Injuries 2Integrated Service Solutions, Inc. Announces Nationwide Expansion for On-site Pipette Calibrations 2Integrated Service Solutions, Inc. Announces Nationwide Expansion for On-site Pipette Calibrations 3Integrated Service Solutions, Inc. Announces Nationwide Expansion for On-site Pipette Calibrations 4AmerisourceBergen to Build Three New Distribution Centers 2
... 1 Merriman Curhan Ford Group, Inc. (Nasdaq: ... Therapeutics, Inc. in the recent merger with Raptor Pharmaceuticals ... company is named "Raptor Pharmaceutical Corp." and commenced trading ... under the ticker symbol "RPTP." , Further details on ...
... 1 Ocular Therapeutix, Inc. announced today the expansion ... Mr. Daniel Myers and Mr. Bernard Haffey. , Mr. ... Alimera Sciences, Inc., a biopharmaceutical company that is developing ... Alimera has raised venture funding totaling approximately $90M. ...
Cached Medicine Technology:Merriman Curhan Ford Acted as Financial Advisor to TorreyPines Therapeutics, Inc. in the Completed Merger With Raptor Pharmaceuticals Corp. 2Ocular Therapeutix, Inc. Appoints Two New Board Members 2
(Date:6/2/2015)... (PRWEB) June 02, 2015 April 8th, ... music venue into Durkin Entertainment’s “RockNRolla Movie Awards” EcoLuxe ... Bend, that gathered some of the world’s top providers ... The event was organized by Debbie Durkin, Los Angeles’ ... film, the EcoLuxe Lounge is a premier red carpet ...
(Date:6/2/2015)... On Wednesday, May 27, 2015, professional driver, Brian Smith, drove ... 207.9 mph. In the process, Hennessey’s potent pony car ... mark. Jay Leno was on hand to witness the ... Garage, which will air on CNBC later this year. , ... oval at the Continental Tire Proving Grounds located in Uvalde, ...
(Date:6/2/2015)... Orlando, FL (PRWEB) June 02, 2015 ... can enjoy quality care in a more convenient location ... Publix in Partin Village Plaza, 2310 E. Irlo Bronson ... location is located less than a mile away from ... with warm décor, more spacious patient areas with digital ...
(Date:6/2/2015)... June 02, 2015 The 3TVPhoenix contest, conducted ... watch the station’s 6:00 a.m. Good Morning Arizona program for ... the station’s Facebook page. , Lisa Allen of ... She plans to apply the monthly $1,000 prize to ... a stay-at-home mom, expressed her surprise and gratitude at winning, ...
(Date:6/2/2015)... The term “Augmented Reality” was coined ... on the real world. Since then many promising technologies ... a map of the vasculature on the surface of ... , AccuVein, the leader in vein visualization, exemplifies this ... and such widespread adoption of its AccuVein AV400 devices ...
Breaking Medicine News(10 mins):Health News:Choices Recovery South Bend Discusses Addiction With Rising Hollywood Star Ben Stillwell 2Health News:774 HP Hennessey Mustang Tested to 207.9 mph 2Health News:Coast Dental Office Opening In Kissimmee with Expanded Technology 2Health News:Scottsdale Resident Named $12,000 Prize Winner- Arizona Central and KTVK 3TV Phoenix Partner in Mortgage Giveaway Contest 2Health News:Vein Visualization Emerges as Premier Augmented Reality Application 2
... March 15 Quantros, a leading healthcare software and services provider of data management, decision support analytics, and clinical business intelligence solutions today ... ... , ... ...
... ... that builds open source platforms and develops advanced research solutions, has ... totaling more than $600,000 to focus research efforts on developing approach-specific, ... is to work towards an interactive simulator that replicates future neurosurgery ...
... traditional screening tests for potential anti-cancer drugs, scientists ... technique that more closely simulates the real-world conditions ... normal cells. Because these neighboring cells key ... microenvironment" can alter the effectiveness of anti-cancer ...
... take the place of a good clinical exam, study finds ... symptoms, but 70 percent of able-bodied professional and collegiate hockey ... MRIs. , "This study was done to see if abnormal ... Dr. Matthew Silvis, an assistant professor in the department of ...
... levels below currently recommended levels did not ... cardiovascular disease events in adults with type 2 diabetes ... events, according to new results from the landmark Action ... Similarly, treating multiple blood lipids with combination drug therapy ...
... MARCH 13, 2010 The announcement of a new ... Artery Bypass Surgery for Effectiveness of Left Main Revascularization), ... graft surgery in patients with left main coronary artery ... Paradigms," a symposium presented by the Cardiovascular Research Foundation. ...
Cached Medicine News:Health News:Quantros Announces Support for Oracle's Enterprise Healthcare Analytics (EHA) Solution to Improve the Quality and Safety of Patient Care 2Health News:Quantros Announces Support for Oracle's Enterprise Healthcare Analytics (EHA) Solution to Improve the Quality and Safety of Patient Care 3Health News:Quantros Announces Support for Oracle's Enterprise Healthcare Analytics (EHA) Solution to Improve the Quality and Safety of Patient Care 4Health News:National Institutes of Health Awards Kitware Over $600,000 to Develop Advancements in Neurosurgical Simulation 2Health News:National Institutes of Health Awards Kitware Over $600,000 to Develop Advancements in Neurosurgical Simulation 3Health News:New cancer drug screening technique more closely mirrors reality 2Health News:New cancer drug screening technique more closely mirrors reality 3Health News:Scans May Be Misleading for Hockey Players 2Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 2Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 3Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 4Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 5Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 6Health News:EXCEL trial will determine safety and efficacy of drug-eluting stents vs. bypass surgery 2
... marketing software enables the efficient capture of ... also has many built-in time saving and ... of name fields and numerous user definable ... data input. The pre-defined options in the ...
... Management software- RLISYS provides ... Software, Support, and Training ... Optometry, Ophthalmology, and Opticianry- ... operations, allowing you to ...
The K-4500 automated hematology analyzer offers fast reliable test results of 18-parameter plus 3-histograms, valuable for effective diagnosis....
The SF-3000 automated hematology analyzer can provide accurate and precise 23-parameter hematolgy results including a fully automated WBC 5-part differential from a compact space-save design....
Medicine Products: